Last reviewed · How we verify
AK112
AK112 is a Small molecule drug developed by Sichuan University. It is currently FDA-approved. Also known as: Pemetrexed, Carboplatin/Cisplatin, Ivonescimab, Carboplatin.
AK112, developed by Sichuan University, is a marketed small molecule with an undisclosed mechanism of action. The key composition patent for AK112 is set to expire in 2028, which may provide a period of market exclusivity. The primary risk for AK112 is the lack of detailed clinical trial results and revenue data, which could affect investor confidence and market adoption.
At a glance
| Generic name | AK112 |
|---|---|
| Also known as | Pemetrexed, Carboplatin/Cisplatin, Ivonescimab, Carboplatin |
| Sponsor | Sichuan University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Phase III Study of AK112 for NSCLC Patients (PHASE3)
- SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC (PHASE2)
- Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study (PHASE2)
- Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors (PHASE1,PHASE2)
- A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer (PHASE2)
- A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC. (PHASE2)
- AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer (PHASE3)
- A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors (PHASE1,PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AK112 CI brief — competitive landscape report
- AK112 updates RSS · CI watch RSS
- Sichuan University portfolio CI
Frequently asked questions about AK112
What is AK112?
Who makes AK112?
Is AK112 also known as anything else?
What development phase is AK112 in?
Related
- Manufacturer: Sichuan University — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Pemetrexed, Carboplatin/Cisplatin, Ivonescimab, Carboplatin
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing